Valuation : Replimune Group, Inc.

Market Cap 1.5B 1.28B 1.21B 1.1B 2.08B 143B 2.09B 14.26B 5.53B 71.99B 5.62B 5.5B 238B P/E 2027 *
-5.49x
P/E 2028 * -6.61x
Enterprise Value 1.4B 1.2B 1.12B 1.03B 1.94B 133B 1.95B 13.31B 5.16B 67.16B 5.24B 5.13B 222B EV / Sales 2027 *
32.6x
EV / Sales 2028 * 7.52x
Free-Float
98.3%
Yield 2027 *
-
Yield 2028 * -
1 day-0.88%
1 week+12.60%
Current month+41.25%
1 month+83.31%
3 months+236.60%
6 months+106.80%
Current year+62.76%
1 week 13.81
Extreme 13.81
16.04
1 month 4.76
Extreme 4.7648
16.04
Current year 1.5
Extreme 1.5
16.04
1 year 1.5
Extreme 1.5
16.04
3 years 1.5
Extreme 1.5
21.32
5 years 1.5
Extreme 1.5
35.93
10 years 1.5
Extreme 1.5
54.85
Manager TitleAgeSince
Chief Executive Officer 55 01/04/2024
Director of Finance/CFO 46 19/09/2023
Chief Tech/Sci/R&D Officer 60 01/12/2022
Director TitleAgeSince
Chairman 54 01/04/2024
Director/Board Member 66 01/07/2017
Chairman 65 01/04/2020
Date Insider Type Main position Quantity % Market Cap.
20/08/26 Don

Founder

-50,000 0.0641%
17/08/26 Sell

Chief Financial Officer

-9,256 0.0119%
11/08/26
Baker Bros. Advisors LP
BuyCompany 2,736,340 3.5056%
Change 5-day change 1-year change 3-year change Capi.($)
-0.88%+12.60%+186.08%-24.09% 1.5B
+0.88%+0.34%+2.69%+23.62% 50.96B
+1.54%+3.45%+475.83%+579.00% 46.18B
-0.62%+1.21%+24.49%+84.88% 42.73B
+0.83%+3.12%+39.86%+19.05% 43.04B
-2.27%-3.02%+14.22%+51.50% 33.48B
-0.18%+1.08%+30.79%+136.68% 17.28B
-0.64%-2.43% - - 16.43B
+0.11%+0.11%+11.88%+28.71% 14.73B
+1.78%+3.47%+85.23%+51.72% 14.09B
Average +0.05%+1.92%+96.78%+105.67% 28.04B
Weighted average by Cap. +0.21%+1.19%+104.30%+142.39%

Financials

2027 *2028 *
Net sales 42.8M 36.74M 34.48M 31.49M 59.43M 4.08B 59.72M 408M 158M 2.06B 161M 157M 6.82B 193M 166M 156M 142M 268M 18.42B 270M 1.84B 714M 9.29B 725M 710M 30.79B
Net income -301M -258M -242M -221M -418M -28.68B -420M -2.87B -1.11B -14.47B -1.13B -1.1B -47.93B -244M -210M -197M -180M -339M -23.31B -341M -2.33B -903M -11.76B -918M -898M -38.95B
Net Debt -100M -86.22M -80.92M -73.91M -139M -9.58B -140M -958M -371M -4.83B -377M -369M -16.01B -44.05M -37.81M -35.49M -32.41M -61.17M -4.2B -61.47M -420M -163M -2.12B -165M -162M -7.02B
Logo Replimune Group, Inc.
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
Employees
465
Date Price Change Volume
27/08/26 $15.82 -0.38% 412,664
26/08/26 $15.88 +0.51% 2,375,263
25/08/26 $15.80 +7.41% 3,136,912
24/08/26 $14.71 -0.41% 2,081,184
21/08/26 $14.77 +5.12% 2,969,475
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
15.88USD
Average target price
19.50USD
Spread / Average Target
+22.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REPL Stock